Novel molecular pathways/targets include endothelial progenitor cells, tyrosine kinase pathway, RhoA/Rho kinase, Vasoactive intestinal peptide (VIP) pathway, and miRNA in PAH therapeutics. Here, VIP is linked to pulmonary arterial hypertension.